BioSpace News Archive

Jaguar announced today the launch of its mental health Entheogen Therapeutics Initiative (ETI) that aims to discover and develop groundbreaking, novel, natural medicines derived from psychoactive plants for treatment of mood disorders, neuro-degenerative diseases, addiction, and other mental health disorders.

Viveve Medical, Inc.today announced that Scott Durbin, chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 3 RALLY study (TNX-CY-F306) of TNX-102 SL 5.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020 . Aggregate orders in July and August

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Patent & Trademark Office (USPTO) has issued US Pat. No. 10,758,567 B2, titled “IN VIVO PRIMING OF NATURAL KILLER CELLS,” which covers a method for treating cancer using INKmune™, a natural killer (NK) cell priming te

- The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) - Esprit BTK was granted breakthrough device designation by the U.S. FDA - There are no stents or drug-coated balloons currently approved for use below the knee in the U.S. [03-September-2020]

HYPERICE , a leading recovery and performance technology brand and innovators of percussion, thermal, vibration and dynamic compression, today announced its partnership with Ja Morant ,

PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPD’s pharmaceutical and biotech customers. This press release features multimedia. View the full release here: https://www.businesswire.c

- This COVID-19 diagnostic tool will validate serological testing for antibodies, helping to fight against the disease - The seroconversion panel will assist diagnostic manufacturers and researchers during assay development and evaluation, as well as troubleshooting COVID-19-test methods

Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, has commercially launched and is now available in the U.S. “The launch of